Itsva data pamishonga inorwisa mavhairasi yeHepatitis B neC

A BATA FreeRelease 8 | eTurboNews | eTN
Avatar of Linda Hohnholz
rakanyorwa Linda Hohnholz

Sainzi yeGiriyedhi nhasi yakazivisa dhata kubva kuzvidzidzo zvakawanda zvinoratidzira kubatsira kwekiriniki nekusiyaniswa kwekurapa kwayo hepatitis, pamwe nekuzvipira kweGiriyedhi mukutsvagisa chiropa kufambisira mberi kubviswa kwehutachiona hwehepatitis muAsia. Iyo data iri kuratidzwa kuMusangano wechi31 weAsia Pacific Association yeChidzidzo cheChiropa (APASL 2022), Kurume 30 - Kubvumbi 3, 2022 muSeoul, South Korea.    

"Iyo data yekiriniki kubva muzvidzidzo zvedu inosimbisa kushanda kwakanyatsosimbiswa uye kuchengetedzeka profiles yemishonga yedu uye inogona kubatsira yekiriniki kune vanhu vanorarama nehepatitis B neC. Aya data anokurudzira anogona kuwedzera kutsigira vatapi vehutano mukuita sarudzo yakakodzera yekurapa kwevarwere vehepatitis. muAsia.” akadaro Betty Chiang, Mutevedzeri weMutungamiriri Wezvekurapa, International, Gilead Sayenzi.

Mashoko kubva kuzvidzidzo zvitatu zvetenofovir (TFV)-based for treatment of hepatitis B (HBV) zvakaratidzwa pamusangano wacho zvakaratidza kuti pakatanga kurapwa varwere vashoma vaiva pangozi shoma yehepatocellular carcinoma (HCC) vakaenderera mberi kusvika panjodzi huru, asi vazhinji vepakati- kana yakakwirira. -ngozi varwere vakagadziridzwa kuderedza njodzi yeHCC mushure menguva refu yeTFV kurapwa.  

Data kubva kuChidzidzo cheChikamu chechipiri cheTFV disoproxil fumarate (TDF) vs. TDF/emtricitabine (FTC) muvarwere vane immune-tolerant (IT) uye zvidzidzo zviviri zvePhase 2, kuenzanisa tenofovir alafenamide (TAF) vs. TDF mune immune-active (IA) ) varwere vakashandiswa kubudisa HCC ngozi yezviitiko nekushandisa Modified PAGE-B (mPAGE-B), chigadziro chekufanotaura 3-gore HCC ngozi (pasi-ngozi [5-≤0], pakati-panjodzi [8-9], uye njodzi huru [≥12]). 

Pakati pevarwere ve126 IT, 106 (84%), 19 (15%) uye 1 (0.8%) vakanga vari pasi, pakati, kana pangozi yakakura, maererano pakutanga. PaVhiki 192, ruzhinji rwakaramba rusina kushanduka kana kuvandudzwa. Hapana varwere veIT vakagadzira HCC. Pakati pevarwere ve1,631 IA (1,092 TAF; 539 TDF-> TAF), 901 (55%), 588 (36%), uye 142 (9%) vakanga vari pasi-, pakati-, kana pangozi yepamusoro, zvichienderana pakutanga. PaVhiki 240, ruzhinji rwakaramba rusina kuchinjwa kana kuvandudzwa; chete 22 (2%) varwere vakatamira kune ngozi yakanyanya. Pakazara, 22 HCC kesi dzakagadzirwa (0.2%, 1.2%, uye 9.2% mumapoka akaderera-, epakati-, uye ane ngozi huru pakutanga).

Rumwe ruzivo rwakaratidzwa pamusangano runopa kuongororwa kwepfupa uye renal kuchengetedza nhoroondo yeTAF pane yeGiriyedhi TAF HBV chirongwa chekiriniki chekuvandudza. Dhata kubva kuvarwere ve1,911 vakarapwa neTAF kana TDF vakaongororwa uye nemhando dzakawanda dzevarwere veHBV, kusanganisira avo vari panjodzi huru yeTDF-yakabatana bhonzo uye / kana renal toxicity. Yakagadzikana kana yakagadziridzwa bhonzo uye renal parameters yakaonekwa neTAF kurapwa kana ichienzaniswa neTDF kurapwa.

Mune hepatitis C, Chidzidzo cheChikamu che3b chakatarisa kurapwa-naïve uye kurapwa-kwakaitika vasingaperi hepatitis C (CHC) varwere muKorea kwakaratidza kuti kurapwa ne sofosbuvir/velpatasvir uye sofosbuvir/velpatasvir/voxilaprevir kwakawana yakakwirira yakasimba virological mhinduro isina-pa-kurapa virologic. kukundikana kana kurapa kwakakomba zviitiko zvakakomba zvakashata. Mune imwe ongororo yekuongorora inogona kuitika zvinodhaka-zvinodhaka kusangana (DDIs) muKorea CHC varwere vachishandisa yakawanda inowanikwa yakananga acting antivirals, sofosbuvir/velpatasvir yakaratidza yakanakira DDI chimiro kunyangwe huwandu hwakanyanya hwekucomorbidity uye komedics pakati pekuchembera kwehuwandu hweCHC muKorea.

Nezvomunyori

Avatar of Linda Hohnholz

Linda Hohnholz

Editor mukuru we eTurboNews yakavakirwa muTN HQ.

Subscribe
Notify of
muenzi
0 Comments
Inline feedbacks
Ona zvese zvataurwa
0
Ndingade pfungwa dzako, ndapota taura.x
Govera ku...